Possible discontinuation of therapies in inflammatory rheumatic diseases - As with initiation of therapies, a shared decision between patient and rheumatologist

摘要

The 2013 Supplement concerns "Possible discontinuation of therapies in inflammatory rheumatic diseases." This topic has long been important to rheumatologists and their patients, for example, historically, in decisions concerning possible discontinuation of gold salts and penicillamine in rheumatoid arthritis, cyclophosphamide in systemic lupus erythematosus (SLE), and other medications in various diseases. It has also been an area in which patient preference often influences tapering or stopping therapies.